Financial Performance - The company's revenue for Q3 2022 was CNY 503,107,079.30, representing a 12.87% increase year-over-year, while the year-to-date revenue was CNY 1,600,442,476.14, showing a slight decrease of 0.24%[6] - Net profit attributable to shareholders for Q3 2022 was CNY 50,723,208.60, up 10.94% year-over-year, and year-to-date net profit was CNY 181,529,635.15, an increase of 20.42%[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was CNY 60,738,939.39, a significant increase of 58.87%, with year-to-date figures at CNY 202,977,663.80, up 65.01%[6] - Total operating revenue for the current period is ¥1,600,442,476.14, slightly down from ¥1,604,249,595.24 in the previous period, representing a decrease of approximately 0.05%[24] - Net profit for the current period is ¥193,924,404.99, an increase from ¥164,737,441.78 in the previous period, marking a growth of approximately 17.7%[27] - Earnings per share (EPS) for the current period is ¥0.1901, compared to ¥0.1579 in the previous period, indicating an increase of about 20.6%[29] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 82,735,899.74, a decrease of 123.09% compared to the previous year[12] - The total cash inflow from operating activities was CNY 1,411,964,994.87, a decrease from CNY 2,077,627,267.70 in the previous period[34] - The net cash flow from operating activities was CNY -82,735,899.74, compared to CNY 358,376,264.22 in the same period last year[34] - Cash inflow from investment activities totaled CNY 57,477,535.37, a decrease from CNY 182,217,654.79 in the prior period[34] - The net cash flow from investment activities was CNY -170,513,451.77, compared to CNY -101,813,587.89 in the previous year[34] - Cash inflow from financing activities was CNY 639,975,120.74, down from CNY 661,864,856.29 in the previous period[34] - The net cash flow from financing activities was CNY 72,135,861.41, a significant improvement from CNY -278,732,981.09 in the same period last year[34] - The ending cash and cash equivalents balance was CNY 396,845,051.72, compared to CNY 461,118,859.68 at the end of the previous year[34] Assets and Liabilities - Total assets at the end of Q3 2022 were CNY 4,130,656,437.04, an increase of 8.53% from the end of the previous year[6] - The total liabilities increased to ¥1,651,328,019.77 from ¥1,518,302,854.27, which is an increase of approximately 8.7%[24] - The total equity attributable to shareholders of the parent company rose to ¥2,360,910,479.58 from ¥2,174,390,029.16, reflecting an increase of about 8.5%[24] - The company has a total current liability of ¥531,468,861.09 in short-term borrowings[20] - The company has a total of 2,190,321,411.28 in non-current assets as of September 30, 2022[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 90,722[13] - Beijing Yabont Technology Co., Ltd. holds 29.12% of shares, totaling 280,563,707 shares, with 144,890,000 shares pledged[13] - Wang Xinya holds 6.75% of shares, totaling 65,000,350 shares, with 65,000,000 shares pledged[13] - The total number of restricted shares at the end of the period is 18,282,038, all held by executives[17] Expenses - The company experienced a 507.89% increase in non-operating expenses, amounting to CNY 964,600.00, primarily due to fines incurred[12] - Research and development expenses for the current period are ¥83,579,820.93, down from ¥86,748,434.26, a decrease of approximately 3.5%[27] - The company reported a financial expense of -¥28,468,689.01, a notable improvement from ¥35,506,385.80 in the previous period[27] Other Financial Metrics - Other comprehensive income attributable to the parent company for the current period is ¥1,604,405.45, compared to -¥4,508,180.01 in the previous period, indicating a significant recovery[29] - Accounts receivable increased by 63.92% to CNY 718,991,700.00, primarily due to an increase in receivables from sales[9] - Inventory as of September 30, 2022, is reported at ¥480,987,788.54, up from ¥375,786,527.20[20] - The company reported a decrease in cash inflow from the recovery of investments, which was CNY 55,000,000.00, down from CNY 180,000,000.00 in the previous period[34] Audit Information - The company did not conduct an audit for the third quarter report[37]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[28]. - Gross profit margin improved to 35%, up from 30% in the same period last year[28]. - The company's operating revenue for the current period is ¥1,097,335,396.84, a decrease of 5.28% compared to the same period last year[36]. - Net profit attributable to shareholders is ¥130,806,426.55, representing a 24.54% increase year-over-year[36]. - The net profit after deducting non-recurring gains and losses is ¥142,238,724.41, which is a 67.78% increase compared to the previous year[36]. - The basic and diluted earnings per share are both ¥0.1370, reflecting a 24.55% increase from the same period last year[36]. - The total assets at the end of the reporting period are ¥4,078,045,272.77, an increase of 7.15% from the end of the previous year[36]. - The net assets attributable to shareholders are ¥2,309,290,570.23, which is a 6.20% increase compared to the previous year[36]. - The weighted average return on equity is 5.83%, up from 5.02% at the end of the previous year[36]. - The company reported a non-recurring loss of ¥48,333,931.87, a significant decrease of 127.63% compared to the previous year's profit of ¥174,928,483.03[36]. Investment and R&D - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[28]. - The company is developing a new line of eco-friendly chemical products, expected to launch in Q4 2022[28]. - The company has three major R&D centers focusing on technology innovation, product innovation, and process optimization[52]. - The company emphasizes continuous R&D investment to ensure technological innovation and maintain industry leadership[59]. - The company has established a new subsidiary in Lanzhou with a total investment of 50 million yuan to boost pesticide intermediate production capacity[57]. - The company invested 25 million yuan to acquire an 11.11% stake in Jiangxi YN Pharmaceutical Co., enhancing its pharmaceutical business capabilities[56]. Market Expansion - User data indicates a 20% increase in active customers, reaching 1 million by the end of June 2022[28]. - The company has expanded its market presence in Southeast Asia, achieving a 25% growth in sales in that region[28]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2022[28]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[28]. Cash Flow and Financial Management - The net cash flow from operating activities was negative at ¥-48,333,931.87, a decline of 127.63% year-on-year, mainly due to reduced cash received from sales[61]. - The company's cash and cash equivalents decreased by ¥96,750,488.03, reflecting a slight decline of 0.45%[61]. - Accounts receivable increased to ¥601,424,280.41, representing 14.75% of total assets, up from 11.52% the previous year[65]. - Inventory rose to ¥451,998,612.30, accounting for 11.08% of total assets, indicating a 1.21% increase[65]. - The company reported a significant increase in investment income, which reached ¥3,130,866.45, a decline of 573.84% year-on-year due to foreign exchange impacts[61]. Environmental Compliance - The company adheres to environmental standards, with wastewater emissions meeting regulatory requirements[142]. - The total wastewater discharge for COD is 1.157 tons per year, with a permitted limit of 15.847 tons per year, indicating compliance with environmental standards[142]. - The company has a comprehensive wastewater treatment facility with a daily processing capacity of 1,000 m³, equipped with advanced technologies such as UV oxidation and MBR membrane treatment[162]. - The company reported a total of 26.609 tons of volatile organic compounds (VOCs) emissions per year, with a compliance standard of VOCs ≤ 80 mg/L[155]. - The company has installed online monitoring facilities for wastewater discharge at its production bases, ensuring real-time compliance with environmental standards[162]. - The company received an administrative penalty of 200,000 RMB for exceeding air emission standards, but it had no significant impact on operations[166]. Risk Management - The company faces risks related to raw material price fluctuations and regulatory changes in the chemical industry[28]. - Raw material prices significantly impact the company's production costs and profitability; effective monitoring and management strategies are in place to mitigate these risks[130]. - The company has a high proportion of foreign sales, primarily settled in USD, making it vulnerable to exchange rate fluctuations; measures are being taken to manage this risk[130]. - The company faces risks from the ongoing COVID-19 pandemic, which could negatively impact production, procurement, and logistics, ultimately affecting performance[129]. Corporate Governance and Compliance - The company has established a risk control system for foreign exchange derivative transactions, with a maximum transaction amount of 80 million USD approved by independent directors[107]. - The company has not engaged in any non-operating fund occupation by major shareholders or related parties during the reporting period[178]. - The company has no significant litigation or arbitration matters during the reporting period[184]. - The company has complied with all environmental impact assessment regulations for its construction projects, ensuring legal compliance[163]. Employee Welfare and Community Engagement - The company has established a comprehensive employee welfare system, including social security, medical insurance, and housing provident fund, ensuring employee rights and health[170]. - The company has made strategic donations, including 200,000 RMB to Fudan University for pandemic prevention efforts[170]. - The company actively engages with investors through various channels, including phone calls and email, to maintain good communication and transparency[169].

Financial Performance - The company's revenue for Q1 2022 was ¥545,435,669.49, representing a 2.83% increase compared to ¥530,442,984.96 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥69,839,686.63, a significant increase of 37.01% from ¥50,972,389.28 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥72,937,631.01, up 72.65% from ¥42,246,397.66 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 545,435,669.49, an increase of 2.1% compared to CNY 530,442,984.96 in Q1 2021[22] - Net profit attributable to shareholders of the parent company reached CNY 69,839,686.63, up 37.1% from CNY 50,972,389.28 in the same period last year[24] - Operating profit for the quarter was CNY 80,629,122.09, an increase of 29.9% compared to CNY 62,077,545.67 in Q1 2021[24] - The total comprehensive income for the quarter was CNY 74,850,213.19, compared to CNY 56,059,033.58 in Q1 2021[26] Assets and Liabilities - The company's total assets at the end of Q1 2022 were ¥3,990,782,525.73, reflecting a 4.85% increase from ¥3,806,025,067.11 at the end of the previous year[3] - Total current assets amounted to CNY 1,850,040,816.33, an increase from CNY 1,659,422,398.73 at the beginning of the year[15] - Total liabilities increased to CNY 1,633,010,099.70, up from CNY 1,518,302,854.27 year-over-year[21] - The company's total equity rose to CNY 2,357,772,426.03, compared to CNY 2,287,722,212.84 in the previous year[21] - The total equity attributable to shareholders at the end of Q1 2022 was ¥2,246,926,260.96, a 3.34% increase from ¥2,174,390,029.16 at the end of the previous year[3] Cash Flow - The net cash flow from operating activities for Q1 2022 was a net outflow of ¥108,978,197.34, which is a 534.16% increase in outflow compared to ¥17,184,530.55 in the same period last year[3] - The company's cash flow from operating activities showed improvement, reflecting better liquidity management[22] - Total cash inflow from operating activities was 448,811,014.84 RMB, down 7.8% from 486,524,248.11 RMB in the previous period[29] - Cash outflow from operating activities totaled 557,789,212.18 RMB, an increase of 10.7% compared to 503,708,778.66 RMB in the previous period[29] - Cash flow from investing activities resulted in a net outflow of -43,739,993.14 RMB, improving from -51,980,914.14 RMB in the previous period[29] - Cash inflow from financing activities was 201,216,860.29 RMB, a decrease of 34.1% from 305,040,952.59 RMB in the previous period[31] - The net cash flow from financing activities was 47,071,102.48 RMB, compared to -11,191,997.90 RMB in the previous period, indicating a positive shift[31] Shareholder Information - The company reported a total of 124,141 common shareholders at the end of the reporting period[11] - The largest shareholder, Alashankou Yaben Venture Capital Co., Ltd., holds 29.12% of the shares[11] - The company has a total of 280,563,707 unrestricted shares held by its top shareholders[11] - The total number of preferred shareholders at the end of the reporting period was zero[15] Inventory and Receivables - The company's inventory at the end of Q1 2022 was ¥504,394,200, representing a 34.22% increase from the previous period, attributed to stockpiling for the second quarter[6] - Accounts receivable increased to CNY 570,024,935.88 from CNY 438,619,701.52, indicating a growth of approximately 30%[15] - Inventory rose to CNY 504,394,213.37 from CNY 375,786,527.20, reflecting a growth of about 34%[17] Research and Development - Research and development expenses for the quarter were CNY 25,245,549.10, slightly up from CNY 24,557,944.82 in Q1 2021[22] Other Financial Metrics - The company's basic earnings per share for Q1 2022 was ¥0.0732, an increase of 37.59% from ¥0.0532 in the previous year[3] - Basic earnings per share increased to CNY 0.0732 from CNY 0.0532 in the same quarter last year[26] - The company experienced a 100% decrease in asset disposal income, reporting zero income for the current period compared to a loss of ¥47,200 in the previous year[8] - The impact of exchange rate changes on cash and cash equivalents was 4,075,629.64 RMB, compared to 11,392,948.35 RMB in the previous period[31]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[22] - The net profit attributable to shareholders was RMB 150 million, an increase of 20% compared to the previous year[22] - The company's operating revenue for 2021 was ¥2,071,740,062.67, representing a year-over-year increase of 3.41% compared to ¥2,003,330,581.54 in 2020[29] - The net profit attributable to shareholders for 2021 was ¥181,849,264.51, which is a 12.94% increase from ¥161,014,430.01 in 2020[29] - The net cash flow from operating activities increased by 25.01% to ¥422,704,008.77 in 2021, up from ¥338,139,531.54 in 2020[29] - The basic and diluted earnings per share for 2021 were both ¥0.1905, reflecting a 13.26% increase from ¥0.1682 in 2020[29] - The total profit amounted to 218.65 million yuan, reflecting a growth of 17.41% year-on-year[70] - Operating profit reached 221.15 million yuan, an increase of 7.78% compared to the previous year[70] Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share in the region by 2023[22] - The future outlook remains positive, with a revenue growth target of 20% for 2022, driven by new product launches and market expansion efforts[22] - The company is focused on expanding its market presence in North America and the Asia-Pacific region with new product launches planned for 2021[57] Research and Development - The company plans to invest 10% of its revenue into R&D for new product development and technological advancements in 2022[22] - The company has three major R&D centers focusing on technological innovation, product innovation, and process optimization[47] - The company has filed for 39 new patents during the reporting period, including 15 invention patents, emphasizing its commitment to innovation and intellectual property protection[76] - The company has ongoing R&D projects focused on microchannel technology and enzyme-catalyzed reactions to enhance safety and efficiency in chemical processes[89] Product Development and Innovation - A new product line in the agricultural chemicals sector is expected to launch in Q3 2022, projected to contribute an additional RMB 200 million in revenue[22] - The company is actively expanding its product range and enhancing its research and development capabilities[49] - The company has developed a low-toxicity fungicide with a significant efficacy against various pathogens, achieving a product yield of 50%[58] - The company has invested heavily in R&D and process optimization, leading to a strong technical advantage in the production of its new pesticide products[57] Risk Management - The management highlighted potential risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[7] - The company faces macroeconomic volatility risks due to global political and military disputes, which may impact its operational performance[153] - Environmental risks are a concern due to potential pollution from chemical production, prompting the company to strengthen safety and environmental measures[154] Governance and Compliance - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations[159] - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance framework[160] - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[161] - The company has established an independent financial accounting system with dedicated financial personnel, ensuring independent financial decision-making and compliance with tax obligations[164] Employee Management - The total number of employees at the end of the reporting period was 1,066, with 191 in the parent company and 875 in major subsidiaries[196] - The company has established a competitive salary system and conducts performance evaluations to motivate employees[199] - The company emphasizes talent cultivation and has developed a comprehensive internal training system for employees[200] Financial Management and Fundraising - The company has raised a total of RMB 847,613,986.89 from the non-public issuance of 105,231,796 shares, after deducting issuance fees of RMB 19,496,012.15[113] - The company has established a dedicated account for raised funds, ensuring strict approval procedures for their use to protect investor interests[113] - The company has not reported any violations in the use and management of raised funds, ensuring timely and accurate disclosures[114]

Financial Performance - The company's operating revenue for the third quarter was ¥445,722,889.64, a decrease of 22.05% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥45,720,021.38, an increase of 43.19% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,232,566.28, a decrease of 1.38% compared to the same period last year[3]. - The basic earnings per share for the quarter was ¥0.0479, up 39.24% year-on-year[3]. - Total operating revenue for the period reached ¥1,604,249,595.24, an increase of 7.1% compared to ¥1,498,116,908.72 in the previous period[26]. - Net profit attributable to the parent company was ¥150,752,618.61, up 22.9% from ¥122,529,265.02 in the same period last year[28]. - The company's total comprehensive income for the period was ¥160,201,287.28, compared to ¥130,710,492.51 in the previous year, marking an increase of 22.5%[32]. - Basic and diluted earnings per share were both ¥0.1579, up from ¥0.1314 in the same period last year, reflecting a growth of 20.0%[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,864,768,949.60, a decrease of 2.49% from the end of the previous year[3]. - The company's total assets amounted to ¥3,864,768,949.60, down from ¥3,963,340,487.18, indicating a decrease of about 2.5%[25]. - The company's total liabilities increased by 41.45% year-to-date, mainly due to an increase in contract liabilities from pre-received payments[7]. - Total liabilities decreased to ¥1,599,681,313.96 from ¥1,798,969,860.27, reflecting a reduction of approximately 11.1%[25]. - The company's total liabilities decreased to RMB 1,331,555,138.08 from RMB 1,491,159,614.92 year-over-year[23]. - Total liabilities amounted to CNY 1,798,969,860.27, a decrease of CNY 12,691,492.31 compared to the previous period[44]. - Current liabilities totaled CNY 1,491,159,614.92, showing a slight decrease of CNY 576,714.11 from the last reporting period[44]. - Non-current liabilities decreased to CNY 307,810,245.35, down by CNY 13,268,206.42 compared to the previous period[44]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥358,376,264.22, an increase of 38.80% year-on-year[3]. - Cash flow from operating activities was ¥1,949,619,608.96, an increase from ¥1,698,046,917.70 in the previous period, showing a growth of 14.8%[33]. - Operating cash inflow for Q3 2021 was CNY 2,077,627,267.70, an increase of 15.3% from CNY 1,801,304,822.01 in Q3 2020[35]. - Total cash and cash equivalents at the end of Q3 2021 stood at CNY 461,118,859.68, down from CNY 326,650,463.83 at the end of Q3 2020[37]. - The company reported a net increase in cash and cash equivalents of CNY -19,271,804.94 for Q3 2021, compared to an increase of CNY 46,222,797.50 in Q3 2020[37]. - The company paid CNY 694,197,363.15 in debt repayments, an increase from CNY 625,728,854.03 in the same quarter last year[37]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,572[16]. - The largest shareholder, Alashankou Yaben Venture Capital Co., Ltd., holds 280,563,707 shares, accounting for 29.12% of the total shares[16]. - The company has a total of 8,623,900 shares repurchased, representing 0.90% of the total shares[19]. Investments and Contracts - A significant contract was signed with Fumish for customized pesticide intermediates production, valued at approximately RMB 2 billion, effective from January 1, 2022, to December 31, 2024[19]. - The company received CNY 180,000,000.00 from investment recoveries, a decrease from CNY 244,300,000.00 in the previous year[35]. Other Financial Metrics - The company's income tax expense for the year-to-date was ¥29,827,800, an increase of 79.38% compared to the same period last year[7]. - Research and development expenses increased to ¥86,748,434.26, representing a rise of 10.5% from ¥78,892,537.34 in the previous year[28]. - Deferred income tax liabilities increased slightly to ¥42,956,025.74 from ¥41,278,066.90, indicating a rise of 4.1%[25]. - The total equity attributable to shareholders of the parent company rose to ¥2,149,443,413.44, an increase of 4.8% from ¥2,050,933,253.39 in the previous period[25]. - The company reported a retained earnings of CNY 393,110,672.74, consistent with the previous period[44]. Audit and Compliance - The company has not undergone an audit for the third quarter report[45]. - The report indicates that the company has implemented new leasing standards starting from 2021[45].

Financial Performance - The company reported a revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 15%[25]. - The gross profit margin for the first half of 2021 was 35%, compared to 30% in the same period last year[25]. - The company's operating revenue for the reporting period was ¥1,158,526,705.60, representing a year-on-year increase of 25.07% compared to ¥926,313,159.19[32]. - The net profit attributable to shareholders was ¥105,032,597.23, an increase of 15.93% from ¥90,599,812.41 in the same period last year[32]. - The net profit after deducting non-recurring gains and losses was ¥84,775,075.83, showing a decrease of 22.38% compared to ¥109,216,831.49 from the previous year[32]. - The net cash flow from operating activities was ¥174,928,483.03, down 41.64% from ¥299,748,347.90 in the previous year[32]. - The total assets at the end of the reporting period were ¥3,957,983,305.41, a slight decrease of 0.14% from ¥3,963,340,487.18 at the end of the previous year[32]. - The net assets attributable to shareholders increased by 2.63% to ¥2,104,863,260.12 from ¥2,050,933,253.39 at the end of the previous year[32]. - The company achieved a revenue of 1,158.53 million CNY, representing a year-on-year growth of 25.07%[50]. - Net profit attributable to shareholders reached 105.03 million CNY, an increase of 15.93% compared to the previous year[50]. Research and Development - The company plans to invest RMB 50 million in R&D for new product development in the next fiscal year[25]. - R&D expenses amounted to 63.07 million CNY, accounting for 5.44% of total revenue, with a year-on-year increase of 36.55%[52]. - The company has applied for 7 invention patents during the reporting period, with a total of 148 authorized patents by the end of the period[52]. - The company is expanding its health business by developing a full industry chain from raw material R&D to brand marketing in dietary supplements[44]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2023[25]. - User data indicates a 20% increase in customer base, reaching 10,000 active users by June 2021[25]. - The management has provided a performance guidance of 10-15% revenue growth for the second half of 2021[25]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[25]. Production and Capacity - A new production facility is set to be operational by Q4 2021, expected to increase production capacity by 25%[25]. - The company is expanding its production capacity at the new facility in Shangyu, which is expected to enhance its pharmaceutical and health product offerings[51]. - The company has launched over ten new health products, including NMN and Coenzyme Q10, to accelerate growth in the health sector[50]. Financial Management and Investments - The total amount of funds raised by the company was RMB 867,109,999.04, with a net amount of RMB 847,613,986.89 after deducting issuance fees[77]. - The company invested RMB 1,667.36 million of the raised funds during the reporting period, with a cumulative investment of RMB 69,585.76 million[75]. - The company reported a fair value change gain of RMB 19,652,554.84 for financial assets during the reporting period[73]. - The company has pledged 51% equity in Anyang Aierwang as collateral for a loan of RMB 41 million from Agricultural Bank of China[72]. Environmental Compliance - The company reported a total wastewater discharge of 4.3435 tons per year for COD, which is below the approved discharge limit of 15.847 tons per year[128]. - The company has one wastewater discharge point located in the southwest corner of the factory, with a COD concentration of 151 mg/L, compliant with local environmental standards[128]. - The company aims to maintain compliance with wastewater discharge standards, including COD ≤ 500 mg/L and BOD ≤ 300 mg/L[132]. - Future expansion plans include enhancing wastewater treatment capabilities to further reduce pollutant levels[134]. Risks and Challenges - The company faces risks related to raw material price fluctuations and has implemented measures to mitigate these risks[7]. - The company faces risks from macroeconomic changes, with potential adverse impacts on performance due to global economic fluctuations and the ongoing effects of the COVID-19 pandemic[114]. - Exchange rate fluctuations pose a risk to the company's export sales, and Yabont Chemical Co., Ltd. is implementing measures such as foreign exchange hedging to manage this risk[115]. Corporate Governance - The company has not distributed cash dividends or issued bonus shares for the reporting period[123]. - The semi-annual financial report has not been audited[150]. - The company has not undergone any bankruptcy restructuring during the reporting period[151]. - The company reported no significant litigation or arbitration matters during the reporting period[152].

Financial Performance - The company's revenue for Q1 2021 was approximately ¥530.44 million, representing a 12.80% increase compared to ¥470.24 million in the same period last year[13]. - Net profit attributable to shareholders decreased by 10.07% to approximately ¥50.97 million from ¥56.68 million year-on-year[13]. - The net profit after deducting non-recurring gains and losses was approximately ¥42.25 million, down 31.56% from ¥61.73 million in the previous year[13]. - Basic and diluted earnings per share were both ¥0.0532, down 9.52% from ¥0.0588 in the previous year[13]. - The weighted average return on equity was 2.45%, a decrease of 0.38% from 2.83% in the previous year[13]. - The company's operating income for the reporting period was 530.44 million yuan, an increase of 12.80% year-on-year, while the net profit attributable to shareholders was 50.97 million yuan, a decrease of 10.07% year-on-year[33]. - The total comprehensive income attributable to the parent company was ¥51,997,167.17, compared to ¥59,923,720.64 in the previous period, reflecting a decrease of about 13%[95]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at approximately -¥17.18 million, a significant decline from ¥298.32 million in the same period last year, representing a decrease of 105.76%[13]. - The net cash flow from operating activities for the reporting period was a net outflow of 17.18 million yuan, a decrease of 105.76% compared to the net inflow of the same period last year, mainly due to a decrease in cash received from sales of goods and an increase in cash paid for purchases[29]. - The cash inflow from operating activities totaled ¥486,524,248.11, down from ¥684,719,240.65 in the previous period, indicating a decrease of approximately 29%[107]. - The ending cash and cash equivalents balance was 411,426,170.38, down from 511,098,075.45 in the previous period[109]. - The company reported a net increase in cash and cash equivalents of 53,842,175.16, compared to 43,266,802.71 in the previous period[113]. - The total cash outflow from investing activities was ¥112,289,675.97, up from ¥86,987,025.05 in the previous period, indicating an increase of about 29%[107]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.10 billion, an increase of 3.41% from ¥3.96 billion at the end of the previous year[13]. - The company's total assets increased to ¥2,690,439,752.58 from ¥2,484,689,584.78, marking a growth of 8.3%[85]. - The total liabilities of the company were CNY 1,878,147,432.45 as of March 31, 2021, compared to CNY 1,798,969,860.27 at the end of 2020, which is an increase of about 4.4%[75][78]. - Total liabilities increased to ¥931,690,155.93, up from ¥746,395,849.61, reflecting a growth of 24.8%[85]. - The company's equity attributable to shareholders reached CNY 2,102,930,420.56, up from CNY 2,050,933,253.39, representing a growth of approximately 2.5%[78]. Investments and Projects - The company has invested a total of ¥69.12 million in fundraising projects, with a cumulative investment of 86.50% in the Nantong base new production line project, expected to be completed by July 31, 2021[48]. - The company has achieved a 24.23% investment completion rate for the Binhai base new production line project, with an expected completion date of May 31, 2021[48]. - The Nantong base's new production line project has been delayed to July 2021 due to production suspension for rectification and safety inspections following the "3.21" chemical plant explosion[51]. - The Binhai base's new production line project has also been postponed to May 2021 due to similar safety and environmental regulations[51]. Market and Operational Strategy - The company is actively promoting the construction of a synthetic biology technology platform and the development of new products, with new health products gradually launched on overseas e-commerce platforms to meet diverse consumer health needs[33]. - The company plans to closely monitor changes in the macroeconomic environment and raw material prices to mitigate risks and ensure stable operations[37]. - The company is focusing on expanding its market presence for new biotechnology products developed through its synthetic biology platform, despite potential risks in market promotion and sales performance[38]. - The company has established a dedicated team for market research and competitive analysis to optimize marketing management for new product sales[38]. Shareholder and Corporate Governance - The company had a total of 35,757 common shareholders at the end of the reporting period[18]. - The company has committed to strict adherence to its promises regarding share transfer limits and management activities, ensuring no unfair benefits are provided to other parties[41]. - The company repurchased 8,623,900 shares, accounting for 0.90% of the total share capital, with a total transaction amount of approximately ¥34.98 million, at a price range of ¥3.82 to ¥4.26 per share[39].

Financial Performance - The company reported a total revenue of RMB 954.69 million for the year 2020, marking a year-on-year increase of 15%[8]. - The net profit attributable to shareholders was RMB 120.45 million, representing a growth of 20% compared to the previous year[8]. - The company's operating revenue for 2020 was CNY 2,003,330,581.54, representing a year-over-year increase of 20.36% from CNY 1,664,423,796.64 in 2019[26]. - The net profit attributable to shareholders for 2020 was CNY 161,014,430.01, a significant increase of 97.22% compared to CNY 81,643,737.20 in 2019[26]. - The net profit after deducting non-recurring gains and losses was CNY 144,224,345.85, up 25.75% from CNY 114,690,626.90 in 2019[26]. - The net cash flow from operating activities reached CNY 338,139,531.54, a remarkable increase of 259.17% from CNY 94,145,833.26 in 2019[26]. - The total assets at the end of 2020 were CNY 3,963,340,487.18, reflecting a 10.74% increase from CNY 3,579,067,760.76 at the end of 2019[26]. - The weighted average return on equity for 2020 was 8.00%, up from 4.10% in 2019[26]. - The company reported a basic earnings per share of CNY 0.1682, which is a 98.35% increase from CNY 0.0848 in 2019[26]. - The company anticipates continued growth in the upcoming year, with a revenue guidance of approximately RMB 1.1 billion for 2021[8]. Market Expansion and Strategy - The company aims to expand its market presence both domestically and internationally, targeting new customer segments and regions[8]. - The company is focusing on expanding its product lines, particularly in the pharmaceutical intermediates sector, which is expected to drive future growth[8]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[8]. - The company has seen a significant increase in long-term equity investments by 923.96%, primarily due to investments in Xiangyang Yuchang Fine Chemical Co., Ltd. and Fuxin Fulongbao Pharmaceutical Technology Co., Ltd.[53]. - The company has established a "core factory + collaborative factory" supply chain management model, enhancing production capacity and operational efficiency[65]. - The company has maintained stable strategic partnerships with major multinational clients, ensuring a strong demand for business expansion[58]. Research and Development - The company is investing in R&D for new products, particularly in the field of fine chemicals and agrochemicals, to enhance its competitive edge[8]. - The company has three major R&D centers focusing on technological innovation, product innovation, process optimization, and achievement transformation[50]. - R&D expenditure amounted to CNY 119.93 million, representing a 12.27% increase year-on-year, accounting for 5.99% of operating revenue[67]. - The company has obtained a total of 139 patents, including 7 international patents, and has 73 pending patent applications[67]. - The company expanded its enzyme library by over 200 entries, bringing the total number of enzyme projects to over 1,000[70]. Product Development and Sales - The company launched its main product, β-Nicotinamide Mononucleotide (NMN), on major domestic e-commerce platforms, breaking the long-standing high price maintained by foreign manufacturers[66]. - The company successfully completed the production and delivery of NMN ton-level orders during the reporting period[70]. - The company is focusing on expanding its product offerings in the pesticide sector, with multiple new formulations in development[96]. - The company is focused on developing environmentally friendly and low-residue pesticide formulations, enhancing its competitive edge in the market[89]. Financial Management and Investments - The company has implemented a stock buyback plan to align the interests of shareholders, the company, and employees[72]. - The company has raised a total of ¥867,109,999.04 through a private placement, with a net amount of ¥847,613,986.89 after deducting issuance costs[150]. - The company has established six dedicated accounts for raised funds, which are still in use as of December 31, 2020[156]. - The company has complied with all regulations regarding the management and disclosure of raised funds, with no violations reported[163]. - The company has decided to repurpose funds from terminated projects for new strategic initiatives, reflecting a proactive approach to market changes[172]. Industry Trends and Market Insights - The pesticide market is projected to reach USD 66.703 billion by 2023, with a compound annual growth rate of 3% from 2018 to 2023[39]. - In 2020, China's pesticide exports reached 2.395 million tons, a year-over-year increase of 29.3%, with export value growing by 14.6% to USD 11.68 billion[40]. - The global pharmaceutical market reached a size of $1.32 trillion in 2019, growing from approximately $1.105 trillion in 2015, with a CAGR of 4.6%[41]. - The global biopharmaceutical market size was $286.4 billion in 2019, accounting for 21.62% of the pharmaceutical market, with a CAGR of 8.7% from 2015 to 2019[41]. - The innovative drug market size was $887.7 billion in 2019, projected to reach $978.7 billion by 2021, representing 66.26% of the global pharmaceutical market[41]. Operational Efficiency - The company's production model is primarily custom processing, with no inventory sales pressure, allowing for tailored production plans based on current orders[52]. - The production capacity utilization rate for pesticide intermediates and active ingredients was 65.00%[76]. - The company is currently expanding its production capacity with ongoing construction projects for enzyme products and pesticide intermediates[76]. - The average selling price of pesticide intermediates decreased by 16.72% in the second half of the year due to the appreciation of the RMB affecting export sales[106]. Risk Management - The company has identified key risks including fluctuations in raw material prices and macroeconomic changes, and has strategies in place to mitigate these risks[8].

雅本化学股份有限公司 2020 年第三季度报告全文 雅本化学股份有限公司 2020 年第三季度报告 雅 本 化 学 2020 年 10 月 1 雅本化学股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人蔡彤、主管会计工作负责人王爱军及会计机构负责人(会计主管 人员)汤小新声明：保证季度报告中财务报表的真实、准确、完整。 2 雅本化学股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|----------------|--------------------------------------------|----------------| ...

雅本化学股份有限公司 2020 年半年度报告全文 雅本化学股份有限公司 ABA CHEMICALS CORPORATION 2020 年半年度报告 雅 本 化 学 | --- | --- | --- | |------------|--------------------|---------| | 股票代码： | 300261 | | | | 股票简称：雅本化学 | | | 披露日期： | 2020 年 8 月 | 25 日 | 1 雅本化学股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人蔡彤、主管会计工作负责人王爱军及会计机构负责人(会计主管 人员)汤小新声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够 的风险认识，并且应当理解计划、预测与 ...